Cost-utility analysis of Ruconest(®) (conestat alfa) compared to Berinert(®) P (human C1 esterase inhibitor) in the treatment of acute, life-threatening angioedema attacks in patients with hereditary angioedema

INTRODUCTION: Administration of human C1 esterase inhibitor (Berinert(®) P) from target import is the most widespread treatment strategy for patients with hereditary angioedema (HAE). However, a therapeutic health program including Ruconest(®) (conestat alfa) could shorten a patient's expectanc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kawalec, Paweł, Holko, Przemysław, Paszulewicz, Anna
Format: Artigo
Idioma:Inglês
Publicat: Termedia Publishing House 2013
Matèries:
Original Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3834719/
https://ncbi.nlm.nih.gov/pubmed/24278067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/pdia.2013.35616
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars